<DOC>
	<DOCNO>NCT00278863</DOCNO>
	<brief_summary>A significant proportion advance gastric cancer ( AGC ) occur individual 65 year age old . In addition , patient delay seek care symptom result diagnosis advance stage see young individual . However , clinical trial gastric cancer rarely available elderly . Recently oral 5-FU pro-drugs , report clinically significant response rate survival mild negligible toxicity , widely use patient AGC . However , study conduct elderly patient .</brief_summary>
	<brief_title>Capecitabine Versus S-1 Elderly Advanced Gastric Cancer ( AGC ) : Randomized Trial</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Pathologically proven gastric gastroesophageal junction adenocarcinoma Metastatic recurrent unresectable disease Measurable lesion ( accord Response Evaluation Criteria Solid Tumors [ RECIST ] ) Age : 6585 year old Performance status : Eastern Cooperative Oncology Group ( ECOG ) 02 Adequate bone marrow function : absolute neutrophile count ( ANC ) ≥ 1,500/ul , platelet count ≥ 100,000/ul , hemoglobin ≥ 9 g/dl ) Adequate renal function ( serum creatinine≤ 1.5 ) Adequate liver function ( serum bilirubin ≤ 2 x upper limit normal [ UNL ] , aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) ≤ 3 x UNL ) No prior chemotherapy ( adjuvant chemotherapy complete least 1 year prior study treatment allow exception capecitabine S1 ) Written informed consent sign patient Previous palliative chemotherapy Known allergy study drug CNS metastasis Significant medical comorbidities Active ongoing infection antibiotic treatment need . Previous ( within 5 year ) history malignancy except cure nonmalignant skin cancer uterine cervical cancer situ .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Stomach cancer</keyword>
	<keyword>Palliative chemotherapy</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>S-1</keyword>
</DOC>